12:00 AM
 | 
Aug 22, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Probuphine buprenorphine: Additional Phase III data

Additional data from a U.S. Phase III trial in 287 patients aged 18-60 with opioid dependence showed that 36% of patients treated with Probuphine had negative urine samples for illicit opioids over 24 weeks vs. 14% for placebo (p<0.0001). Additionally, Probuphine significantly improved clinician-rated global severity of opioid dependence (p=0.0003) and clinician-rated global improvement vs. placebo (p=0.0002). Furthermore, there were no significant...

Read the full 288 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >